Adriana Naidel
Surgical · Venice, FLNPI 1487070389
Payments from drug & device makers
Across 51 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$198
- Radius Health, Inc.$168
- Eisai Inc.$125
- Novo Nordisk$110
- Lilly USA, LLC$78
- Bayer$64
- plus $557 from 17 others
What the payments were for
- Food & beverage$1,28799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $198 |
| Radius Health, Inc. | 8 | $168 |
| Eisai Inc. | 1 | $125 |
| Novo Nordisk | 5 | $110 |
| Lilly USA, LLC | 4 | $78 |
| Bayer | 2 | $64 |
| Almatica Pharma LLC | 3 | $50 |
| Biotronik Inc. | 2 | $49 |
| Kyowa Kirin, Inc. | 2 | $48 |
| AstraZeneca | 2 | $48 |
| AbbVie | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Recordati_rare_diseases_inc. | 2 | $44 |
| Insulet Corporation | 1 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Sandoz | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,301 in reported general payments places this provider in the 65th percentile of 1,018 surgical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 43 | $94,590 |
| TymlosAbaloparatide | 14 | $42,780 |
| ProliaDenosumab | 11 | $19,346 |
| Ibandronate Sodium | 165 | $4,472 |
| SynthroidLevothyroxine Sodium | 40 | $3,594 |
| Levothyroxine Sodium | 188 | $1,735 |
| Raloxifene Hcl | 18 | $1,263 |
| Liothyronine Sodium | 24 | $673 |
| Alendronate Sodium | 96 | $585 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 17 | $178 |
| Hydrochlorothiazide | 18 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $168 | $42,78014 claims |
| AmgenProlia | $198 | $19,34611 claims |
| AbbVieSynthroid | $47 | $3,59440 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $1,735188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,018 surgical providers in Florida.
Other surgical in Venice
- Aaron SookhooBrandon$742K
- Jessica McCarrySt Petersburg$445K
- Harmony ChurchTallahassee$265K
- Matthew HammondPensacola$155K
- Pamela LiggettMiami$120K
- Stephanie CarrollPalm Beach Gardens$114K
- Christina NauglePalm Beach Gardens$96K
- Kathleen McMichaelClearwater$96K
- Michael SullivanSarasota$91K
- Dana ZeitlerNaples$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.